title: Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report.
abstract: The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite standard treatment, the patient developed progressive bone metastases and stopped conventional therapy in June 2007. Starting in October 2007, the patient was treated with LHT, oncolytic virotherapy and DC vaccination. Prostate-specific antigen (PSA)-levels, with the highest level of 233.8 ng/ml in January 2008, decreased to 0.8 ng/ml in late February 2008. In March 2008, a reduction in bone metastases could be detected by positron emission tomography/computed tomography. Since then, the PSA levels have remained low and the patient is doing well. The treatment induced a long-lasting antitumor memory T-cell response. This possibly explains the long-term effectiveness of this novel experimental combined treatment approach.
authors.affiliation: Immunological and Oncological Center, Cologne, Germany ; German Cancer Research Center, Division of Translational Immunology, Heidelberg, Germany.
authors.forename: Volker
authors.initials: V
authors.lastname: Schirrmacher
authors.affiliation: Immunological and Oncological Center, Cologne, Germany.
authors.forename: Akos-Sigmund
authors.initials: AS
authors.lastname: Bihari
authors.affiliation: Immunological and Oncological Center, Cologne, Germany.
authors.forename: Wilfried
authors.initials: W
authors.lastname: Stücker
authors.affiliation: Immunological and Oncological Center, Cologne, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Sprenger
keywords: Newcastle disease virus; dendritic cell vaccination; hyperthermia; immunotherapy; prostate cancer